Mahana Therapeutics Plans To Use $61M In Series B Financing To Launch IBS Treatment App
Mahana is planning a 2022 nationwide launch of its FDA-cleared prescription digital therapeutic for treating symptoms of irritable bowel syndrome.
You may also be interested in...
In an interview with Medtech Insight, Andy Molnar, new CEO of the Digital Therapeutics Alliance, outlines some of the big issues facing the digital therapeutics industry, which has seen tremendous growth during the pandemic.
After raising $73m in a series D in March, Happify Health is recruiting patients in a real-world study to further evaluate its behavioral health app.
Dexcom is making CGM data available through consumer devices starting with Garmin’s smartwatches and bicycle computers.